Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Phase III research

Biologic medicine effective against refractory psoriatic arthritis

Trial supports the use of ixekizumab as an option for patients who are unable to take TNF inhibitors.

Hands with psoriatic arthritis

Source: CID – ISM / Science Photo Library

Researchers conclude that ixekizumab is an alternative option for difficult-to-treat psoriatic arthritis.

There are limited treatment options for people with psoriatic arthritis who either do not respond to or are unable to take tumour necrosis factor (TNF) inhibitors.

In a phase III trial, published in The Lancet[1] (online, 24 May 2017), 363 people with refractory psoriatic arthritis were randomly assigned to placebo or ixekizumab, a monoclonal antibody that targets interleukin 17A, administered every two or four weeks.

After 24 weeks, more people who received ixekizumab every four weeks had at least a 20% significant improvement in the American College of Rheumatology response criteria compared with those who received placebo (53% vs 20%). The same was also true of people who received ixekizumab every two weeks (48%).

The researchers conclude that ixekizumab, which has already been shown to be effective in treatment-naive patients, is an alternative option for difficult-to-treat psoriatic arthritis patients who have had an inadequate response, or intolerance, to TNF inhibitors.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2017.20202937

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Hands with psoriatic arthritis

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.